News

Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
STAT3h
Pharmalittle: We’re reading about a Lilly deal, a gene therapy shock for Duchenne families, and more
In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.
Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story
Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...
Fierce Pharma1d
Eli Lilly adds high-dose Zepbound options to lineup of cheaper vials available on self-pay website
Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...
STAT2h
Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion
Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.
Explore more
KYMA1d
Eli Lilly announces price cut for Zepbound
Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.
WISH-TV19h
Learn how Lilly employees help Edna Martin Christian Center
Eli Lilly employees join forces for community service with Connecting Hearts at Home initiative in central Indiana, ...